STAT Stitch Deep Dive Podcast Beyond The Bedside

STAT Stitch Deep Dive Podcast Beyond The Bedside

di Regular Guy

Corsi Scienza della vita

Stagione 5

ATI/ OB | Hypertensive Complications

https://statstitch.etsy.com Hypertensive disorders are a leading cause of maternal and fetal morbidity and mortality worldwide. The underlying pathophysiology of these conditions stems from poor placental trophoblast invasion and inadequate uterine spiral artery remodeling during early pregnancy. This structural failure causes placental hypoxia, which triggers a systemic inflammatory cascade leading to widespread maternal endothelial dysfunction, vasoconstriction, and subsequent end-organ damage. Chronic Hypertension: Blood pressure (BP) greater than or equal to 140/90 mm Hg identified prior to 20 weeks of gestation. Gestational Hypertension: New-onset BP greater than or equal to 140/90 mm Hg occurring after 20 weeks of gestation, without the presence of proteinuria. Preeclampsia: Diagnosed when hypertension occurs after 20 weeks alongside systemic end-organ damage, with or without proteinuria. It is subdivided into preeclampsia without severe features and preeclampsia with severe features (BP ≥ 160/110 mm Hg, central nervous system dysfunction, pulmonary edema, or altered liver function). Eclampsia: A severe obstetrical emergency characterized by new-onset tonic-clonic seizures that can rapidly cause maternal hypoxia, placental abruption, and fetal or maternal death. HELLP Syndrome: A life-threatening variant involving Hemolysis, Elevated Liver enzymes, and Low Platelets. Key Clinical Manifestations and Monitoring Because these disorders can deteriorate rapidly, recognizing the warning signs is the most vital nursing intervention. Manifestations of worsening disease include severe and unresolved headaches, visual disturbances, right upper quadrant or epigastric abdominal pain, pulmonary edema, and sudden weight gain. Accurate BP measurement using the correct cuff size with the client seated for 10 minutes is critical. Diagnostic laboratory monitoring focuses on falling platelet counts (< 100,000/mm3), rising AST/ALT liver enzymes, elevated serum creatinine (≥ 1.1 mg/dL), and proteinuria (≥ 300 mg in a 24-hour urine test). Core Treatments and Therapies Antihypertensives: First-line oral medications for maintenance include methyldopa, labetalol, and nifedipine. For acute severe hypertension (BP ≥ 160/110), IV labetalol or IV hydralazine is rapidly administered. ACE inhibitors and ARBs are strictly contraindicated in pregnancy due to the high risk of fetal anomalies. Low-dose aspirin (81 mg) is highly recommended as a preventative measure for at-risk clients. Seizure Prophylaxis: Intravenous Magnesium Sulfate is the gold standard medication for preventing and treating eclamptic seizures. Because it is a potent central nervous system depressant, nurses must vigilantly monitor for magnesium toxicity, marked by loss of deep tendon reflexes, respiratory depression, and oliguria. Calcium gluconate must be readily available as the antidote. A low-stimulation environment and an indwelling catheter for strict intake/output are required. Fetal Protection: Antenatal corticosteroids, such as betamethasone, are administered to accelerate fetal lung surfactant production if a premature birth is anticipated. Fetal status is closely monitored via frequent ultrasounds and nonstress tests due to the high risk of fetal growth restriction and hypoxia.

ATI/ OB | Hemorrhagic Complications

https://statstitch.etsy.com Early Pregnancy Bleeding Disorders Spontaneous Abortion (Miscarriage): Ends up to 26% of pregnancies, mostly due to fetal chromosomal anomalies. Management includes expectant waiting, medical expulsion using misoprostol or mifepristone, or procedural evacuation via suction curettage. Ectopic Pregnancy: An embryo implants outside the uterus, most commonly in the fallopian tubes. A ruptured ectopic pregnancy is a life-threatening emergency due to high hemorrhage risk. It presents with vaginal bleeding and sharp abdominal pain. Treatment requires methotrexate (for stable cases) or surgery (salpingectomy). Molar Pregnancy: Abnormal trophoblastic/placental growth without a normal viable embryo. It presents with severely elevated hCG levels and "prune juice" appearing bleeding. Patients must undergo serial hCG monitoring and avoid pregnancy post-surgery to ensure the tissue does not develop into gestational trophoblastic neoplasia (cancer). Mid-to-Late Pregnancy Complications Cervical Insufficiency: Painless cervical dilation causing mid-trimester pregnancy loss. Treated with progesterone or a surgical cervical cerclage (placed around 13-14 weeks and removed at 36-37 weeks). Placenta Previa: The placenta implants near or completely covers the internal cervical os. It famously presents as painless vaginal bleeding in the second half of pregnancy. Crucial Nursing Rule: Never perform a digital vaginal exam on these clients, as it can puncture the placenta and cause catastrophic hemorrhage. Treatment typically requires planned cesarean birth. Placental Abruption: Premature separation of the placenta from the uterine wall. It presents with sudden bleeding, severe abdominal pain, and a rigid, board-like abdomen. This is a massive medical emergency causing fetal hypoxia and maternal shock, frequently requiring an urgent emergency cesarean birth. Clotting Disorders in Pregnancy Pregnancy induces a prothrombotic (hypercoagulable) state, drastically increasing the risk for deep vein thrombosis (DVT) and pulmonary embolism (PE). Disorders include inherited thrombophilias (e.g., Factor V Leiden) and acquired conditions like Antiphospholipid Syndrome (APS), which can cause recurrent miscarriages. Treatment primarily involves anticoagulation with Low Molecular Weight Heparin (LMWH). While these clients are prone to clots, the required anticoagulants place them at a high risk for postpartum hemorrhage, demanding vigilant postpartum monitoring. Core Nursing Priorities for All Conditions Hemodynamic Stabilization: Monitor vital signs closely for hypovolemic shock (tachycardia, hypotension), measure strict intake and output by weighing pads to quantify blood loss, and establish large-bore IV access for fluid resuscitation and blood transfusions. Fetal Monitoring: Continuously assess fetal heart tones for nonreassuring patterns indicating hypoxia. Alloimmunization Prevention: Administer Rho(D) immune globulin to all Rh-negative clients experiencing bleeding or pregnancy loss to protect future pregnancies.

OB/ PHARM | Betamethasone

https://statstitch.etsy.com Betamethasone is a synthetic glucocorticoid utilized primarily for its anti-inflammatory and immunosuppressive properties. It is available in systemic forms (injectable and oral) and topical formulations, which range from medium potency, such as betamethasone valerate, to high or very high potency, such as betamethasone dipropionate. Mechanism of Action At the cellular level, betamethasone works by inducing lipocortins, which inhibit phospholipase A2. This action prevents the breakdown of lysosomal membranes and stops the release of arachidonic acid, thereby halting the production of endogenous inflammatory mediators such as prostaglandins, kinins, and histamine. This blocks early inflammatory processes like vascular permeability and leukocyte movement, as well as later processes like collagen deposition and scar formation, ultimately resulting in decreased swelling, redness, itching, and scaling of the skin. Pharmacokinetics and Absorption The drug can be administered orally, topically, or via multiple injection routes (intramuscular, intravenous, intra-articular, etc.). Systemically absorbed betamethasone is metabolized by the CYP3A4 enzyme, binds weakly to plasma proteins, and has a biological half-life of 35 to 54 hours. For topical applications, systemic absorption increases dramatically if the skin is damaged, inflamed, occluded, or naturally thin (such as on the eyelids, face, or genitalia). Once absorbed through the skin, topical corticosteroids enter the exact same pharmacokinetic pathways as systemically administered forms. Key Adverse Reactions Betamethasone carries an extensive risk profile, especially with prolonged use or high systemic absorption. Severe Reactions: Notable severe risks include skin atrophy (occurring in up to 33% of cases), increased intracranial pressure, bone fractures, avascular necrosis, gastrointestinal perforation, and severe cardiovascular issues like heart failure, myocardial infarction, or stroke. Moderate Reactions: The highest-frequency moderate risk is hypothalamic-pituitary-adrenal (HPA) axis suppression, which occurs in up to 73% of cases. Other significant moderate risks include Cushing's syndrome, hyperglycemia, immunosuppression, and osteoporosis. Mild Reactions: Localized issues such as pruritus, maculopapular rash, skin irritation, and xerosis occur in 1-10% of users. Pregnancy and Lactation Guidelines Pregnancy: Use requires extreme caution. Systemic use has been associated with cleft palate, stillbirth, and premature abortion. While it is sometimes used off-label to induce fetal lung maturation in preterm birth scenarios, chronic use is discouraged. Pregnant women should avoid using potent topical steroids in large amounts; using over 300 grams of potent topical corticosteroids in the third trimester significantly increases the risk of fetal growth restriction and low birth weight. Lactation: The drug is excreted in breast milk and could theoretically suppress infant growth or natural corticosteroid production, but oral use is still generally considered acceptable during breastfeeding. Topical use is also deemed safe by dermatologists, provided extreme care is taken to ensure the infant does not come into direct physical contact with the applied area.

OB/ PHARM | Methotrexate (WARNING)

https://statstitch.etsy.com Methotrexate Overview and Indications Methotrexate is a folate antimetabolite used to treat malignant diseases (such as breast cancer, lymphoma, and leukemia) and nonmalignant autoimmune diseases (including rheumatoid arthritis, psoriasis, and juvenile idiopathic arthritis). Because of its high potential for severe and sometimes fatal toxicities, methotrexate must only be prescribed by an experienced clinician. Mechanism of Action The drug competitively inhibits dihydrofolate reductase, an enzyme required to convert folic acid into reduced folates. This action severely blocks DNA synthesis, repair, and cellular replication, heavily impacting rapidly dividing tissues like cancer cells, bone marrow, and fetal cells. In autoimmune diseases, methotrexate acts as an immunosuppressant and anti-inflammatory primarily by inhibiting the enzyme AICAR transformylase, which selectively impairs T and B lymphocyte replication and alters adenosine concentrations. Core 80/20 Safety Profile: Boxed Warnings & Severe Risks The vast majority of critical clinical management revolves around monitoring and preventing its severe, potentially fatal adverse reactions: Pregnancy & Teratogenicity: Methotrexate is strictly contraindicated in pregnant patients treated for nonmalignant diseases. It causes intrauterine fetal death and severe congenital anomalies, with studies showing a 42.5% rate of spontaneous abortion in exposed pregnancies. Both female and male patients must use effective contraception during treatment and for 3 to 6 months afterward due to risks of teratogenicity and chromosomal damage to sperm. Bone Marrow Suppression: The drug causes profound myelosuppression, including neutropenia and aplastic anemia, which can lead to fatal infections. This risk is unexpectedly heightened if administered concurrently with nonsteroidal anti-inflammatory drugs (NSAIDs). Hepatotoxicity: Methotrexate can trigger irreversible liver damage, fibrosis, and cirrhosis after prolonged use. It is strictly contraindicated in patients with alcoholism or chronic liver disease. Routine liver function monitoring is required, and high-risk or long-term patients (such as those with psoriasis) may require periodic liver biopsies or noninvasive fibrosis assessments. Pulmonary Toxicity: Potentially fatal acute or chronic interstitial pneumonitis can occur at any time and at any dose. A dry, nonproductive cough demands immediate investigation and potential drug discontinuation. Dermatologic Reactions: Patients may develop rapid, fatal skin reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. It also sensitizes the skin to radiation, meaning patients can experience "recall" reactions from prior sunburns or radiation therapy. Renal Toxicity: Because the drug is cleared by the kidneys, impaired renal function causes dangerous drug accumulation. High-dose IV regimens can precipitate in renal tubules, causing acute renal failure; preventing this requires aggressive hydration and urine alkalinization (pH of 7 or higher). Gastrointestinal Toxicity: Methotrexate can cause severe ulcerative stomatitis, diarrhea, hemorrhagic enteritis, and fatal GI perforation. It must be used with extreme caution in patients with peptic ulcer disease or ulcerative colitis.

OB/ Pharm | Labetalol

https://statstitch.etsy.com Labetalol is an oral and parenteral medication primarily utilized for the management of hypertension. It functions as a combined selective, competitive alpha1-blocker and nonselective, competitive beta-blocker. Labetalol effectively targets beta1-receptors in the heart, beta2-receptors in bronchial and vascular smooth muscle, and alpha1-receptors in vascular smooth muscle. The drug's pharmacodynamic action is driven primarily by its beta-blocking capabilities, but the ratio of alpha- to beta-receptor activity shifts based on the route of administration: it is 1:3 when administered orally and 1:7 when administered intravenously. The alpha1-blocking component is critical because it inhibits peripheral vasoconstriction, lowering systemic vascular resistance without compromising total peripheral blood flow, which minimizes the reductions in cardiac output commonly seen with standard beta-blockers. Administration & Dosing Oral Administration: Labetalol is completely absorbed from the gastrointestinal tract, but due to extensive first-pass metabolism, its absolute bioavailability is only 25% (though taking it with food increases this absorption). Peak plasma concentrations occur within 1 to 2 hours, and peak effects happen within 2 to 4 hours. The full antihypertensive effect is visible within 1 to 3 hours, allowing clinicians to safely ensure there is no exaggerated hypotensive response during an office visit. Intravenous (IV) Administration: Patients must be kept in a supine position during IV administration, and blood pressure must be closely monitored before, during, and after administration. Direct IV injections require no dilution and should be pushed slowly over 2 minutes. For continuous infusion, the initial rate is 2 mg/minute, which is subsequently adjusted based on the patient's blood pressure response. The maximum effect of an IV dose is seen rapidly, within just 5 minutes. Providers should stop the IV infusion once a satisfactory blood pressure response is achieved and transition to oral labetalol as soon as the patient's supine blood pressure begins to rise. Adverse Reactions & Safety Profile One of the most notable and common adverse effects is orthostatic hypotension, which has an incidence rate of up to 58% and is especially prevalent following intravenous use. Severe adverse reactions include hepatotoxicity, hepatic necrosis, myocardial infarction, AV block, heart failure, cardiac arrest, bronchospasm, and severe allergic responses like angioedema. Mild to moderate adverse reactions frequently encompass nausea (up to 19%), dizziness (up to 16%), fatigue, nasal congestion, elevated hepatic enzymes, and ejaculation or erectile dysfunction. Pregnancy and Lactation Labetalol is frequently used to manage hypertension during pregnancy, a condition that inherently increases maternal and fetal risks such as preeclampsia and intrauterine growth restriction. While labetalol crosses the placenta, extensive medical experience has not identified a drug-associated risk for major birth defects. However, healthcare providers must carefully monitor neonates born to treated mothers for signs of hypotension, bradycardia, hypoglycemia, and respiratory depression. For lactating mothers, labetalol is generally considered compatible with breast-feeding, as only minuscule amounts (approximately 0.004% of the maternal dose) are excreted in human milk. Despite this, alternative beta-blockers like propranolol may be preferred for mothers nursing premature infants

OB/ PHARM | Nifedipine

Overview & Mechanism of Action Nifedipine is an oral dihydropyridine calcium-channel blocker primarily used to treat hypertension, variant (Prinzmetal's) angina, and chronic stable angina. It works by inhibiting the influx of extracellular calcium through the membrane pores of myocardial and vascular smooth muscle cells, effectively plugging the channels. Unlike other calcium channel blockers (such as verapamil and diltiazem) that act evenly on the SA/AV nodes and vasculature, nifedipine acts predominantly as a potent peripheral vasodilator with negligible effects on AV nodal conduction. This vasodilation decreases total peripheral resistance, systemic blood pressure, and afterload. For variant angina, it increases myocardial oxygen supply by inducing coronary vasodilation; for chronic stable angina, it decreases myocardial oxygen demand by reducing afterload. Administration Guidelines Proper administration is critical for nifedipine's safety and efficacy: Oral Dosing: Immediate-release capsules and sustained-release tablets must be swallowed whole; they should never be crushed, broken, or chewed. Patients should be advised that empty tablet shells may appear in their stool, which is normal and not clinically significant. While regular doses can be taken with meals to prevent gastric irritation, the specific formulation Adalat CC should be taken on an empty stomach. Formulation Interchangeability: Two 30 mg Adalat CC tablets can be safely interchanged with one 60 mg tablet. However, three 30 mg tablets are strictly not interchangeable with a single 90 mg tablet, as this combination results in a substantially higher peak plasma concentration (Cmax). Sublingual Route Warning: Sublingual administration of nifedipine liquid to rapidly lower blood pressure (such as in hypertensive urgency) has generated controversy, is generally not recommended, and offers no bioavailability advantage over swallowing the capsules whole. Grapefruit Interaction: Patients must avoid grapefruit juice before or after drug administration. Co-administration increases nifedipine's peak plasma concentrations and overall exposure (AUC) by two-fold. Pharmacokinetics Nifedipine is rapidly and well-absorbed (90%) but undergoes extensive first-pass metabolism in the liver, resulting in an absolute bioavailability of 50% to 70%. It is highly protein-bound (92% to 98%) and undergoes rapid hepatic metabolism into inactive metabolites. Because it is a CYP3A4 substrate, its metabolism can be significantly altered by CYP3A4 inhibitors or inducers. The drug has an elimination half-life of roughly 2 to 5 hours. While immediate-release capsules peak within 30 minutes to 2 hours, sustained-release tablets peak at around 6 hours, allowing for convenient once-daily dosing. Adverse Reactions Due to its potent vasodilatory effects, the most common mild-to-moderate side effects include peripheral edema (4.0-30.0%), dizziness (4.0-27.0%), flushing (0-25.0%), and headaches (10.0-23.0%). Severe, though less common, adverse reactions can include heart failure, myocardial infarction, arrhythmias, gastrointestinal bleeding, and Stevens-Johnson syndrome.

OB/ PHARM | Methergine (WARNING)

https://statstitch.etsy.com Methergine (methylergonovine) is an oral and parenteral semisynthetic ergot alkaloid derivative classified as a labor inducer. It is primarily indicated for the management and prevention of postpartum uterine atony, subinvolution of the uterus, and postpartum hemorrhage following the delivery of the placenta or the anterior shoulder. Mechanism of Action The drug acts directly on uterine smooth muscle to increase the tone, rate, amplitude, strength, duration, and frequency of rhythmic contractions. This rapid and sustained tetanic uterotonic effect reduces blood loss and shortens the third stage of labor. Pharmacologically, methylergonovine is a selective antagonist of serotonin receptors in various smooth muscles, a partial agonist of serotonin in umbilical and placental blood vessels, and a partial agonist of alpha-adrenergic receptors in blood vessels. This makes it a potent vasoconstrictor, which can cause coronary vasospasm and a decrease in luminal diameter, particularly after parenteral administration. Handling and Safety Classified as a hazardous drug on the NIOSH Group 3 and Draft 2020 Table 2 lists, Methergine requires strict handling precautions. Healthcare workers must use double chemotherapy gloves and protective gowns when handling injectable or oral liquid forms. Eye, face, and respiratory protection may also be required, and manipulating or crushing oral tablets necessitates additional protective equipment to prevent exposure. Administration and Dosage The drug has a duration of action of approximately three hours across all administration routes: Oral: Administered as 0.2 mg 3 to 4 times daily for up to 7 days postpartum. It has roughly a 60% bioavailability, with a slower absorption rate in postpartum females compared to healthy adult males. The onset of action occurs in 5 to 10 minutes. Intramuscular (IM): This is the preferred parenteral route due to a lower incidence of side effects. A 0.2 mg dose is injected deeply into a large muscle, with an onset of 2 to 5 minutes. Doses can be repeated every 2 to 4 hours as needed. Intravenous (IV): IV administration is not routinely recommended and should only be used as a strict life-saving measure due to the severe risk of inducing sudden hypertensive and cerebrovascular accidents. It must be given slowly over a period of no less than 60 seconds. Onset is immediate, resulting in a strong oxytocic, cardiovascular, and cerebrovascular response. Periarterial or intraarterial injection must be strictly avoided. Parenteral solutions must be visually inspected and discarded if they are discolored or not clear. Monitoring and Adverse Reactions Due to its strong vasoconstrictive properties, providers must closely monitor the patient's blood pressure, heart rate, and uterine response prior to and during administration. Adverse reactions include: Severe: Stroke, myocardial infarction, ventricular fibrillation, seizures, uterine rupture, water intoxication, and anaphylactoid reactions. Pharmacokinetics and Drug Interactions Methylergonovine is highly unstable when exposed to tropical conditions of heat, light, and moisture. It has a short elimination half-life, is rapidly eliminated, and is extensively metabolized by the liver, with less than 5% of an oral dose excreted in urine. No drug accumulation occurs with repeated oral dosing. Importantly, the use of CYP3A4 inhibitors can increase the risk of severe ergot toxicity,

OB/ PHARM | Terbutaline

https://statstitch.etsy.com Overview and Mechanism of Action Terbutaline sulfate is a short-acting selective beta-2 agonist (SABA) utilized primarily for the treatment and prevention of bronchospasms associated with asthma and COPD. It functions by stimulating beta-2 adrenergic receptors, which are densely located on bronchiolar smooth muscle. This stimulation activates the enzyme adenyl cyclase, leading to an increase in cyclic adenosine monophosphate (cAMP). The resulting elevation in cAMP causes vasodilation and significant relaxation of bronchial smooth muscle, thereby increasing bronchial airflow. The Boxed Warning on Tocolysis The most critical clinical safety information regarding terbutaline involves its off-label use for managing premature labor, or tocolysis. Because beta-2 stimulation induces uterine relaxation, it has historically been used to suppress contractions; however, this practice carries a severe Boxed Warning. Oral terbutaline is strictly contraindicated for the prevention or treatment of preterm labor due to a complete lack of demonstrated efficacy, severe maternal cardiovascular safety concerns, and the risk of neonatal hypoglycemia. Furthermore, injectable terbutaline must never be utilized for prolonged tocolysis, defined as administration beyond 48 to 72 hours. Prolonged use has resulted in 16 maternal deaths and 12 serious maternal cardiovascular events reported to the FDA during post-marketing surveillance. Severe maternal adverse reactions include pulmonary edema, myocardial ischemia, cardiac arrhythmias, and hypokalemia. Acute, short-term use of injectable terbutaline is restricted to briefly prolonging pregnancy for 2 to 7 days, allowing just enough time for hospital transfer and the administration of antenatal corticosteroids for fetal lung maturation. Administration and Pharmacokinetics Terbutaline can be administered orally, subcutaneously, intravenously, or via inhalation. Oral tablets may be crushed, though administering them with food reduces bioavailability by approximately one-third. Subcutaneous injections should be administered in the lateral deltoid area. While the drug can be diluted for intravenous use, continuous IV infusion is notably not FDA-approved. The onset of therapeutic action depends heavily on the route: 5 to 30 minutes for inhalation, 30 to 60 minutes for subcutaneous injection, and 1 to 2 hours for oral doses. Bronchodilation typically lasts between 3 to 8 hours. Crucially, continuous use of beta-2 agonists over a 12-month period can dangerously accelerate the decline of lung function in asthmatic patients. Strict dose adjustments are required for renal impairment: patients with a creatinine clearance of 10–50 ml/min should receive exactly 50% of the usual systemic dose, and the drug must be completely avoided if clearance drops below 10 ml/min. Adverse Reactions and Lactation Because beta-receptors are also present in the heart, terbutaline is inherently cardiostimulatory. The most common mild adverse reaction is a tremor, which affects between 8% and 38% of patients. Other frequent side effects include drowsiness, headaches, palpitations, and sinus tachycardia. Severe but less common reactions include seizures, pulmonary edema, and the exacerbation of arrhythmias, alongside metabolic shifts such as hypokalemia and hyperglycemia. For lactating mothers, terbutaline is excreted in breast milk in minimal amounts. While the American Academy of Pediatrics considers it usually compatible with breastfeeding, inhaled beta-agonists (like albuterol) are heavily preferred over systemic terbutaline.

(WARNING) Tag Explained

this episode explains the (WARNING) tag

Youtube Update

This is an episode of me giving a YouTube update

13 di 34